Department of Gynecology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Augustenburger Platz 1, Berlin, Germany.
Tumorbank Ovarian Cancer Network, Berlin, Germany.
Ann Surg Oncol. 2023 Jan;30(1):35-45. doi: 10.1245/s10434-022-12459-3. Epub 2022 Sep 9.
This study seeks to evaluate the impact of breast cancer (BRCA) gene status on tumor dissemination pattern, surgical outcome and survival in a multicenter cohort of paired primary ovarian cancer (pOC) and recurrent ovarian cancer (rOC).
Medical records and follow-up data from 190 patients were gathered retrospectively. All patients had surgery at pOC and at least one further rOC surgery at four European high-volume centers. Patients were divided into one cohort with confirmed mutation for BRCA1 and/or BRCA2 (BRCAmut) and a second cohort with BRCA wild type or unknown (BRCAwt). Patterns of tumor presentation, surgical outcome and survival data were analyzed between the two groups.
Patients with BRCAmut disease were on average 4 years younger and had significantly more tumor involvement upon diagnosis. Patients with BRCAmut disease showed higher debulking rates at all stages. Multivariate analysis showed that only patient age had significant predictive value for complete tumor resection in pOC. At rOC, however, only BRCAmut status significantly correlated with optimal debulking. Patients with BRCAmut disease showed significantly prolonged overall survival (OS) by 24.3 months. Progression-free survival (PFS) was prolonged in the BRCAmut group at all stages as well, reaching statistical significance during recurrence.
Patients with BRCAmut disease showed a more aggressive course of disease with earlier onset and more extensive tumor dissemination at pOC. However, surgical outcome and OS were significantly better in patients with BRCAmut disease compared with patients with BRCAwt disease. We therefore propose to consider BRCAmut status in regard to patient selection for cytoreductive surgery, especially in rOC.
本研究旨在评估乳腺癌(BRCA)基因状态对多中心配对原发性卵巢癌(pOC)和复发性卵巢癌(rOC)患者肿瘤播散模式、手术结果和生存的影响。
回顾性收集了 190 名患者的病历和随访数据。所有患者均在 pOC 接受手术,并在欧洲四个高容量中心至少进行了一次进一步的 rOC 手术。患者分为 BRCA1 和/或 BRCA2 突变证实(BRCAmut)组和 BRCA 野生型或未知(BRCAwt)组。分析两组患者的肿瘤表现模式、手术结果和生存数据。
BRCAmut 疾病患者的平均年龄年轻 4 岁,诊断时肿瘤受累程度明显更高。BRCAmut 疾病患者在所有分期的肿瘤减灭术率均较高。多变量分析显示,只有患者年龄对 pOC 完全肿瘤切除有显著预测价值。然而,在 rOC 中,只有 BRCAmut 状态与最佳肿瘤减灭显著相关。BRCAmut 疾病患者的总生存(OS)显著延长 24.3 个月。BRCAmut 组在所有分期的无进展生存(PFS)均延长,在复发时达到统计学意义。
BRCAmut 疾病患者在 pOC 时疾病进展更具侵袭性,发病更早,肿瘤播散更广泛。然而,与 BRCAwt 疾病患者相比,BRCAmut 疾病患者的手术结果和 OS 显著更好。因此,我们建议在考虑进行细胞减灭术的患者选择时,考虑 BRCAmut 状态,尤其是在 rOC。